SLC5A2 and heart failure: We needed to answer the question if sodium-glucose transporter-2 (SGLT-2) inhibitors provide any beneficial role in symptomatic burden, functional status, the composite of hospitalization for heart failure or cardiovascular mortality (HHF/CVM), and all-cause mortality (ACM) in patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).